Acucela and Otsuka Pharmaceutical Receive FDA Fast Track Designation for ACU-4429 in Patients with D- Diabetes Professional Diabetes Site

Acucela and Otsuka Pharmaceutical Receive FDA Fast Track Designation for ACU-4429 in Patients with D

Time:10-04-05 07:30

Author:admin

BOTHELL Wash. & TOKYO----Acucela Inc. a clinical-stage biotechnology corporation focused on developing new treatments for blinding eye diseases and Otsuka Pharmaceutical Co. Ltd. today announced ...

BOTHELL Wash. & TOKYO----Acucela Inc. a clinical-stage biotechnology corporation focused on developing new treatments for blinding eye diseases and Otsuka Pharmaceutical Co. Ltd. today announced that they have received Fast Track designation from the U.S.

News tag: acucela otsuka pharmaceutical

to publish commentsee all comment

Related informationPublish news

Acucela And Otsuka Pharmaceutical Receive FDA Fast Track Designation For ACU-4429 In Patients With D	Diabetes' link to eating disorders explored (Science Daily)
Acucela and Otsuka Pharmaceutical Receive FDA Fast Track Designation for ACU-4429 in Patients with D	Israeli Company Develops Bionic Retina Implant (Israel National News)
Dr. Arnall Patz dies at 89; helped eliminate major cause of blindness (Los Angeles Times)	Quarter of Lankans are diabetic (Daily News)
Dr. Arnall Patz director emeritus at the Wilmer Eye Institute dies at 89 (Baltimore Sun)	In the Zone: D-Y's Miller a success story (Cape Cod Times)